Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics prepares clinical development program of sevuparin in sepsis/septic shock
(1) STOCKHOLM, SWEDEN - March 10, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics is preparing a clinical development program of its drug candidate sevuparin in patients suffering from sepsis/septic shock, and possibly also other severe inflammatory conditions arising in conjunction with major trauma, surgery, autoimmunity and viral infections. Modus Therapeutics expects to start the first clinical trial in this new indication around the end of 2021. Sevuparin has already demonstrated a favorable safety profile in clinical...